Clinical trials
MDS clinical trials
Below are recruiting mds clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07328191Recruiting
Transfusion guided by quality of life for MDS or AML
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
NiceAges 18 years+ - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07400341RecruitingPhase 2
Romiplostim vs rhTPO for platelet recovery after transplant
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
Suzhou, JiangsuAges 18–65 - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT07607418RecruitingPhase 2
Ivosidenib maintenance therapy for IDH1-mutated blood cancers
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT07761533RecruitingPhase 1/Phase 2
PBSS1113 plus azacitidine for blood cancers
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT03680677Recruiting
Checking frailty to guide treatment in older blood cancer patients
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
Philadelphia, PennsylvaniaAges 60 years+ - NCT04608110RecruitingPhase 1
Novel therapy for myelodysplastic syndrome
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
Bunkyō CityAges 20 years+ - NCT06670222RecruitingPhase 1
Arsenic for low-risk MDS
This study tests an oral form of arsenic in people with low-risk myelodysplastic syndromes (MDS) who need regular red blood cell transfusions and haven't gotten enough benefit from standard treatments. It aims to see if this drug can help reduce transfusion needs.
NiceAges 18 years+ - NCT05554835Recruiting
Mitochondrial disease registry and history study
This study collects information about people who have a suspected or confirmed mitochondrial disease. It aims to better understand how the disease looks over time, which can help future treatments.
InnsbruckAges Any age - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06976736Recruiting
Long-term follow-up for TScan TCR-T therapy patients
This study follows participants who previously received a TCR-T cell therapy in a TScan-sponsored trial to monitor long-term effects.
Duarte, CaliforniaAges 18–110 - NCT03850418RecruitingPhase 2
Azacitidine for blood chimerism changes after transplant
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Detroit, MichiganAges 18–75 - NCT06156579RecruitingPhase 2
Venetoclax and Decitabine for Relapsed or Refractory AML
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07702578RecruitingPhase 3
Study of special donor T-cells for blood stem cell transplant
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
Gilbert, ArizonaAges 18 years+ - NCT06471946RecruitingPhase 1/Phase 2
Stem cell transplant for older patients with high-risk MDS
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06664970Enrolling by invitationPhase 2
Treatment for MDS/MPN Overlap Syndrome
This study tests a combination of two drugs (azacitidine or ruxolitinib plus selinexor) for people with MDS/MPN overlap syndrome, a type of blood cancer. It aims to see if this treatment helps control symptoms and improve blood counts.
BeijingAges 18 years+ - NCT05009537Recruiting
Optical genome testing for blood cancer diagnosis
This study tests a special way of looking at chromosomes to help diagnose blood-related cancers or blood disorders. If you’re having samples taken for chromosome testing, this trial may use your sample to see if the method helps with diagnosis.
BrestAges Any age - NCT04187105RecruitingPhase 2
Total marrow radiation using a targeted intensity plan before transplant
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
Chicago, IllinoisAges 18–75 - NCT05925504RecruitingPhase 2
Lowering luspatercept dose for lower-risk myelodysplastic anemia
This Phase 2 study tests whether gradually lowering the dose of luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) who have anemia. It may help reduce side effects while still improving blood counts or symptoms.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06717958RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML or MDS
This trial tests whether taking ivosidenib after a stem cell transplant can help prevent leukemia from coming back in people with a specific gene change called IDH1. It may be an option if you have AML or MDS with that mutation and are recovering from transplant.
AachenAges 18–75 - NCT07396480RecruitingPhase 3
Add-on Venetoclax before stem cell transplant for AML/MDS
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
Fuzhou, FujianAges 50–75 - NCT06972641RecruitingPhase 2/Phase 3
Gene-based maintenance therapy after stem cell transplant
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 14–75
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mds?
- Yes. Clin2 currently lists 139 recruiting mds studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mds trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mds trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.